Quick Takeaways
- This page summarizes Raymond M. Jordt's Form 4 filing for Altimmune, Inc. (ALT).
- 1 reported transaction and 0 derivative rows are listed below.
- Filing timestamp: 02 Feb 2026, 16:10.
Raymond M. Jordt - 31 Jan 2026 Form 4 Insider Report for Altimmune, Inc. (ALT)
- Signature
- /s/ Gregory Weaver, as Attorney-in-Fact
- Issuer symbol
- ALT
- Transactions as of
- 31 Jan 2026
- Net transactions value
- +$14,033
- Form type
- 4
- Filing time
- 02 Feb 2026, 16:10:06 UTC
- Previous filing
- 29 Jan 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"Raymond M. Jordt filed Form 4 for Altimmune, Inc. (ALT) on 02 Feb 2026."
What Changed
- Previous filing in this sequence was filed on 29 Jan 2026.
- Current net transaction value: +$14,033.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Official SEC Source
Reporting Owners (1)
| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Jordt Raymond M | Chief Business Officer | 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG | /s/ Gregory Weaver, as Attorney-in-Fact | 02 Feb 2026 | 0001960780 |
Transactions Table
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ALT | Common Stock, par value $0.0001 | Award | $14,033 | +4,571 | +7% | $3.07 | 70,107 | 31 Jan 2026 | Direct | F1, F2 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Raymond M. Jordt is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2025 through January 31, 2026. |
| F2 | In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on August 1, 2025. |